Lupin-Aptar Launch India’s First Smart Device For MDIs At $22 Apiece

Move Ties-In With Lupin's Respiratory Ambitions

Nov 27 2019

• By Vibha Ravi

Listen to this article

As the Indian pharma industry catches up with digitization, Lupin partners with Aptar to launch a smart device for MDIs. While there is a need for the product, whether it will find favor in a price-sensitive market remains to be seen.

SC1805_Digital Partners_465653942_1200.jpg — Digital Partnerships On The Rise In India • Source: Shutterstock

With an eye on the rising number of tech-savvy patients and health care personnel (HCP) relying on digital information, Lupin Ltd. has partnered with Aptar Pharma to introduce India’s first smart device for metered-dose inhalers (MDIs). The device brand name, Adhero, plays on its intended end-benefit of adherence to therapy among those with chronic respiratory diseases.

Inhalers are the preferred delivery option for managing a rising incidence of chronic respiratory diseases like asthma and chronic obstructive...

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio
Jan 23 2026
• By Jessica Merrill
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
Quick Listen: Scrip’s Five Must-Know Things
Dec 09 2025
• By Reed Miller
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Article Without An Author Listed
Nov 19 2025
Here is a short description.
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Jul 15 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone
Jun 18 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Finance Watch: Biopharma IPOs On The Upswing, Including Ex-US Offerings
Jun 17 2026
ghghghghghjhjhjhj